Ironwood Historical Income Statement
| IRWD Stock | USD 3.52 0.15 4.09% |
Historical analysis of Ironwood Pharmaceuticals income statement accounts such as Total Revenue of 231.7 M or Gross Profit of 224 M can show how well Ironwood Pharmaceuticals performed in making a profits. Evaluating Ironwood Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Ironwood Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Ironwood Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ironwood Pharmaceuticals is a good buy for the upcoming year.
Ironwood |
About Ironwood Income Statement Analysis
Ironwood Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Ironwood Pharmaceuticals shareholders. The income statement also shows Ironwood investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Ironwood Pharmaceuticals Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Ironwood Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Ironwood Pharmaceuticals minus its cost of goods sold. It is profit before Ironwood Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Ironwood Pharmaceuticals. It is also known as Ironwood Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Ironwood Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Ironwood Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.At present, Ironwood Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 235.7 M, whereas Interest Expense is forecasted to decline to about 19.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 31.2M | 7.6M | 21.6M | 19.9M | Depreciation And Amortization | 1.5M | 1.4M | 1.6M | 1.5M |
Ironwood Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Ironwood Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ironwood Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 297K | 3.6M | 1.5M | 1.4M | 1.6M | 1.5M | |
| Interest Expense | 36.6M | 29.5M | 31.2M | 7.6M | 21.6M | 19.9M | |
| Total Revenue | 428.4M | 389.5M | 413.8M | 410.6M | 442.7M | 231.7M | |
| Gross Profit | 404.5M | 386.4M | 412.2M | 409.2M | 441.2M | 224.0M | |
| Other Operating Expenses | 311.4M | 231.2M | 181.5M | 160.3M | 233.7M | 243.2M | |
| Operating Income | 120.1M | 142.9M | 232.3M | 250.3M | 209.0M | 219.5M | |
| Ebit | 120.1M | 138.3M | 231.8M | 260.0M | (926.4M) | (880.1M) | |
| Research Development | 115.0M | 88.1M | 70.4M | 44.3M | 116.1M | 108.7M | |
| Ebitda | 120.4M | 141.9M | 233.3M | 261.4M | (924.9M) | (878.6M) | |
| Cost Of Revenue | 23.9M | 3.1M | 1.5M | 1.4M | 1.6M | 1.5M | |
| Total Operating Expenses | 287.5M | 228.1M | 181.5M | 160.3M | 232.1M | 235.7M | |
| Income Before Tax | 58.9M | 108.9M | 200.7M | 252.4M | (948.1M) | (900.7M) | |
| Total Other Income Expense Net | (61.2M) | (34.1M) | (31.6M) | 2.1M | (1.2B) | (1.1B) | |
| Net Income | (15.3M) | 106.2M | 528.4M | 175.1M | (1.0B) | (952.1M) | |
| Income Tax Expense | 74.3M | 2.7M | (327.8M) | 77.4M | 83.5M | 87.7M | |
| Selling General Administrative | 172.5M | 140.0M | 111.1M | 116.0M | 148.0M | 138.7M | |
| Net Income From Continuing Ops | 58.9M | 106.2M | 528.4M | 175.1M | (980.9M) | (931.9M) | |
| Non Operating Income Net Other | (24.6M) | (4.6M) | (452K) | 9.7M | 8.7M | 9.2M | |
| Net Income Applicable To Common Shares | 21.5M | 106.2M | 528.4M | 175.1M | 201.3M | 211.4M | |
| Non Recurring | 309K | 167.7M | 3.6M | 15.4M | 17.7M | 16.8M | |
| Interest Income | 2.9M | 1.5M | 726K | 9.5M | 23.2M | 24.4M | |
| Net Interest Income | (33.7M) | (28.0M) | (30.4M) | 1.9M | 8.5M | 8.9M | |
| Reconciled Depreciation | 5.6M | 3.6M | 1.5M | 1.4M | 1.4M | 1.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.